Sichuan Province Shuzhong Pharmacy Co., Ltd.

Primary objective: To investigate the bioequivalence of ondansetron hydrochloride tablets (8 mg (C18H19N3O)) manufactured by Sichuan Yike Pharmaceutical Co., Ltd. as the test formulation and ondansetron hydrochloride tablets (8 mg (C18H19N3O); trade name: ZOFRAN®) manufactured by BEXAL FARMACéUTICA, S.A. as the reference formulation in healthy human subjects, in accordance with the relevant regulations for bioequivalence studies. Secondary objective: To observe the safety of the test and reference formulations in healthy trial participants.

Primary Objective: This study used vonoprazan fumarate tablets (20 mg (C17H16FN3O2S)) certified by Sichuan Yike Pharmaceutical Co., Ltd. as the test formulation and vonoprazan fumarate tablets (trade name: Walker, 20 mg (C17H16FN3O2S)) certified by Takeda Pharmaceutical Company Limited as the reference formulation. A human bioequivalence study was conducted under fasting and postprandial conditions to evaluate the bioequivalence of the test and reference formulations in healthy participants. Secondary Objective: To observe the safety of the test and reference formulations in healthy participants.

Flunarizine hydrochloride capsules (5mg (C26H26F2N2)) from Sichuan Yike Pharmaceutical Co., Ltd. were used as the test formulation, and flunarizine hydrochloride capsules (5mg (C26H26F2N2)) from Xi'an Janssen Pharmaceutical Co., Ltd. were used as the reference formulation. The bioequivalence of the two formulations in healthy human subjects was investigated in accordance with the relevant regulations for bioequivalence testing.